Expansion of the lineup with Kanarb complexes… a clinical trial of combining it with Lipitor

Published: 2015-01-30 13:18:28

Updated: 2015-01-30 13:52:27

Boryung Pharmaceutical is advancing on clinical trials to expand its lineup with the self-developed hypertension treatment ‘Kanarb’ complex.

According to the Ministry of Food and Drug Safety on the 28^th, Boryung Pharmaceutical has acquiredan approval to conducta Phase 1 clinical trial for Kanarb and the hyperlipidemia treatment ‘Lipitor (atorvastatin)’.

The clinical trial is to assess pharmac...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.